Norman Fields Gottscho Capital Management LLC Has $5.36 Million Stock Position in Novo Nordisk A/S (NYSE:NVO)

Norman Fields Gottscho Capital Management LLC raised its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 21.2% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 77,212 shares of the company's stock after buying an additional 13,480 shares during the quarter. Novo Nordisk A/S accounts for about 1.8% of Norman Fields Gottscho Capital Management LLC's holdings, making the stock its 13th biggest position. Norman Fields Gottscho Capital Management LLC's holdings in Novo Nordisk A/S were worth $5,362,000 as of its most recent filing with the SEC.

Several other large investors have also recently added to or reduced their stakes in NVO. GQG Partners LLC increased its stake in shares of Novo Nordisk A/S by 74.7% during the 4th quarter. GQG Partners LLC now owns 12,994,533 shares of the company's stock worth $1,117,790,000 after purchasing an additional 5,556,460 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Novo Nordisk A/S during the 4th quarter worth $404,910,000. Loomis Sayles & Co. L P boosted its holdings in shares of Novo Nordisk A/S by 34.2% during the 4th quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company's stock worth $995,397,000 after buying an additional 2,947,771 shares during the period. Nuveen Asset Management LLC boosted its holdings in shares of Novo Nordisk A/S by 73.2% during the 4th quarter. Nuveen Asset Management LLC now owns 6,244,931 shares of the company's stock worth $537,189,000 after buying an additional 2,639,693 shares during the period. Finally, Two Sigma Investments LP bought a new stake in shares of Novo Nordisk A/S during the 4th quarter worth $158,657,000. Institutional investors and hedge funds own 11.54% of the company's stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on NVO shares. BMO Capital Markets reaffirmed a "market perform" rating and set a $64.00 price objective (down from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They set an "equal weight" rating for the company. Dbs Bank downgraded shares of Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th. Kepler Capital Markets raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Thursday, March 13th. Finally, Wall Street Zen raised shares of Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a report on Friday, April 25th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, four have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $128.00.

Novo Nordisk A/S Price Performance

Shares of NVO stock traded up $1.94 during mid-day trading on Friday, reaching $71.40. The company's stock had a trading volume of 11,185,051 shares, compared to its average volume of 6,800,832. Novo Nordisk A/S has a 1-year low of $57.00 and a 1-year high of $148.15. The company has a market cap of $320.41 billion, a P/E ratio of 21.70, a PEG ratio of 0.90 and a beta of 0.65. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The firm's 50-day moving average is $65.58 and its two-hundred day moving average is $81.59.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.92. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. The company had revenue of $11.87 billion during the quarter. On average, research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.